AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

A new mRNA injection turns immune cells into cancer-fighting CAR-T cells — inside the body. Faster, cheaper, and potentially ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...

In this week’s edition of InnovationRx, we look at the health impact of the Republican spending bill, a startup that built a hospital in India to test its AI software, the impact of the vaccine panel ...

A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...